Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: JAMA Oncol. 2017 Oct 1;3(10):1393–1398. doi: 10.1001/jamaoncol.2016.3600

Figure.

Figure

Use of active surveillance (AS) and watchful waiting (WW) in Sweden from 2009–2014. Results are shown by age group and clinical risk category: very low-risk (clinical stage T1c, Gleason score ≤6, PSA <10 ng/ml, PSA density <0.15ng/ml/cm3, <8mm total cancer length in ≤4 positive biopsy cores)[8], low-risk (T1–T2, Gleason score ≤6 and PSA <10ng/ml), and intermediate-risk (T1–T2 with Gleason score 7 and/or PSA 10–20ng/ml).